Johnson & Johnson (NYSE:JNJ) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 779,061 shares of the company’s stock after selling 8,405 shares during the quarter. Johnson & Johnson accounts for about 0.4% of Nisa Investment Advisors LLC’s investment portfolio, making the stock its 29th largest holding. Nisa Investment Advisors LLC’s holdings in Johnson & Johnson were worth $112,668,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. IFS Advisors LLC lifted its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. Highline Wealth Partners LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth about $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson in the third quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in Johnson & Johnson by 58.7% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after acquiring an additional 91 shares in the last quarter. Finally, Activest Wealth Management acquired a new stake in Johnson & Johnson in the third quarter valued at approximately $40,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $146.76 on Friday. The stock has a market capitalization of $353.34 billion, a P/E ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. The firm’s 50-day moving average price is $147.99 and its two-hundred day moving average price is $155.98. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22,438,500 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.29 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Raymond James decreased their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research note on Thursday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Wolfe Research initiated coverage on Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price objective for the company. Finally, Stifel Nicolaus cut their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $170.06.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.